rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2023-537-544rsp-3388Research ArticleПРОБЛЕМЫ РЕВМАТОЛОГИИ В ПЕРИОД ПАНДЕМИИ КОРОНОВИРУСНОЙ БОЛЕЗНИ 2019PROBLEMS OF RHEUMATOLOGY DURING THE 2019 CORONAVIRUS PANDEMICЧастота и течение COVID-19 у больных ревматическими заболеваниями (по данным ФГБНУ НИИР им. В.А. Насоновой)Frequency and course of COVID-19 in patients with rheumatic diseases (according to the data of V.A. Nasonova Research Institute of Rheumatology)https://orcid.org/0000-0003-1040-313XКуликовА. Н.KulikovA. N.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

ankulikov93@gmail.comhttps://orcid.org/0000-0003-4327-6720МуравьеваН. В.MuravyevaN. V.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

n-muravjeva@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

115522, Москва, Каширское шоссе, 34а

115522, Moscow, Kashirskoye Highway, 34A

belovbor@yandex.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202327102023615537544Copyright © Куликов А.Н., Муравьева Н.В., Белов Б.С., 20232023Куликов А.Н., Муравьева Н.В., Белов Б.С.Kulikov A.N., Muravyeva N.V., Belov B.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/3388

Цель исследования – изучить частоту и тяжесть перенесенного COVID-19 в когорте пациентов с ревматическими заболеваниями (РЗ), находившихся на стационарном лечении в ФГБНУ НИИР им. В.А. Насоновой. Материал и методы. В исследование были отобраны содержащие информацию о наличии или отсутствии новой коронавирусной инфекции (COVID-19) истории болезни 6911 пациентов с иммуновоспалительными РЗ (ИВРЗ) и 362 больных остеоартритом (ОА), находившихся на стационарном лечении в ФГБНУ НИИР им. В.А. Насоновой с 21 сентября 2021 г. по 28 апреля 2023 г. Результаты. Частота COVID-19 при анализируемых ИВРЗ оказалась статистически значимо выше по сравнению с таковой при ОА (р<0,001). Для всех включенных в анализ нозологий характерно увеличение риска заболеваемости COVID-19 при сопоставлении с ОА в 2,7–6,3 раза. Пациентам с ревматоидным артритом, анкилозирующим спондилитом, псориатическим артритом, микрокристаллическими артритами, болезнью Шегрена, системной склеродермией, системной красной волчанкой и АНЦА-ассоциированными васкулитами статистически значимо чаще (p < 0,02) проводилась терапия COVID-19 по сравнению с контрольной группой. Для пациентов с этими нозологиями характерно увеличение риска потребности в лечении по поводу COVID-19 в 1,9–3,7 раза в сравнении с пациентами с ОА. У пациентов с воспалительными заболеваниями суставов, системными заболеваниями соединительной ткани и системными васкулитами потребность в госпитализации при развитии COVID-19 оказалось статистически значимо выше по сравнению с больными ОА (р=0,01, p=0,007 и р=0,024 соответственно). Для указанных трех групп характерно нарастание риска госпитализаций в 4,3–4,7 раза. Кроме того, для больных ИВРЗ пожилого и старческого возраста характерен нарастающий риск потребности в лечении, госпитализации и назначении генно-инженерных биологических препаратов или таргетных синтетических базисных противовоспалительных препаратов по поводу COVID-19. Заключение. Согласно полученным результатам, проблема COVID-19 является значимой для пациентов с РЗ, что диктует необходимость проведения исследований по вакцинопрофилактике этой инфекции у данной категории больных.

The aim of the study was to assess frequency and severity of COVID-19 in patients with rheumatic diseases (RD) who were on inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology. Patients and methods. The study included information on the presence or absence of COVID-19 in the medical history of 6911 patients with immunoinflammatory RD (IIRD) and 362 patients with osteoarthritis (OA) who were on inpatient treatment at the V.A. Nasonova Research Institute of Rheumatology from September 21, 2021 to April 28, 2023. Results. The incidence of COVID-19 in the analyzed IIRD was significantly higher compared to OA (p<0.001). All IIRD included in the analysis are characterized by an increased risk of COVID-19 incidence when compared with OA by 2.7–6.3 times. Patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, microcrystalline arthritis, Sjögren’s disease, systemic sclerosis, systemic lupus erythematosus, and ANCA-associated vasculitis were significantly more likely (p<0.02) to receive COVID-19 therapy compared with the control group. Patients with these diseases are characterized by an increased risk of treatment for COVID-19 by 1.9–3.7 times compared with OA. Also, patients with inflammatory joint diseases (IJD), connective tissue diseases (CTDs) and systemic vasculitis (SV) were hospitalized with COVID-19 more often than patients with OA (p=0.01, p=0.007 and p=0.024, respectively). Patients with IJD, CTDs and SV are characterized by an increased risk of hospitalization with COVID-19 by 4.3– 4.7 times compared with OA. In addition, elderly patients with IIRD are characterized by an increasing risk of treatment, hospitalization and use of biologics or targeted synthetic disease-modifying drugs for COVID-19. Conclusion. According to the results obtained, the problem of COVID-19 is significant for patients with RD, which dictates need for further research on vaccination against SARS-CoV-2 among this cohort of patients.

иммуновоспалительные ревматические заболеванияCOVID-19эпидемиологиязаболеваемостьвоспалительные заболевания суставовсистемные заболевания соединительной тканисистемные васкулитыimmuno-inflammatory rheumatic diseasesCOVID-19epidemiologymorbidityinflammatory joint diseasesconnective tissue diseasessystemic vasculitisИсследование выполнено в рамках научно-исследовательской работы ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» (№ государственного задания 1021051503137-7).ReferencesThe top 10 causes of death. URL: https://www.who.int/newsroom/fact-sheets/detail/the-top-10-causes-of-death/ (Accessed: 28th June 2023).The top 10 causes of death. URL: https://www.who.int/newsroom/fact-sheets/detail/the-top-10-causes-of-death/ (Accessed: 28th June 2023).WHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who.int/ (Accessed: 28th June 2023).WHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who.int/ (Accessed: 28th June 2023).WHO Director-General’s opening remarks at the media briefing – 5 May 2023. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-mediabriefing---5-may-2023. (Accessed: 28th June 2023).WHO Director-General’s opening remarks at the media briefing – 5 May 2023. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-mediabriefing---5-may-2023. (Accessed: 28th June 2023).Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-1242. doi: 10.1001/jama.2020.2648Ярошецкий АИ, Грицан АИ, Авдеев СН, Власенко АВ, Еременко АА, Заболотских ИБ, и др. Диагностика и интенсивная терапия острого респираторного дистресс-синдрома (Клинические рекомендации Общероссийской общественной организации «Федерация анестезиологов и реаниматологов»). Анестезиология и реаниматология. 2020;(2):5-39. doi: 10.17116/anaesthesiology20200215Yaroshetsky AI, Gritsan AI, Avdeev SN, Vlasenko AV, Eremenko AA, Zabolotskikh IB, et al. Diagnostics and intensive therapy of acute respiratory distress syndrome (Clinical guidelines of the Federation of Anesthesiologists and Reanimatologists of Russia). Russian Journal of Anesthesiology and Reanimatology. 2020;(2):5-39 (In Russ.). doi: 10.17116/ anaesthesiology20200215Zhou X, Cheng Z, Luo L, Zhu Y, Lin W, Ming Z, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021;201:23-29. doi: 10.1016/j.thromres.2021.02.010Zhou X, Cheng Z, Luo L, Zhu Y, Lin W, Ming Z, et al. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb Res. 2021;201:23-29. doi: 10.1016/j.thromres.2021.02.010Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458. doi: 10.1002/jmv.26424Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021;93(3):1449-1458. doi: 10.1002/jmv.26424Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: Systematic review and meta-analysis. BMJ Nutr Prev Health. 2022;5(1):10-18. doi: 10.1136/bmjnph-2021-000375Sawadogo W, Tsegaye M, Gizaw A, Adera T. Overweight and obesity as risk factors for COVID-19-associated hospitalisations and death: Systematic review and meta-analysis. BMJ Nutr Prev Health. 2022;5(1):10-18. doi: 10.1136/bmjnph-2021-000375Белов БС, Гриднева ГИ, Аронова ЕС, Муравьева НВ. К вопросу о скрининге и профилактике хронических и оппортунистических инфекций в ревматологии. Антибиотики и химиотерапия. 2023;68(1-2):69-76. doi: 10.37489/0235-2990-2023-68-1-2-69-76Belov BS, Gridneva GI, Aronova ES, Muravyeva NV. On the issue of screening and prevention of chronic and opportunistic infections in rheumatology. Antibiotics and Chemotherapy. 2023;68(1-2):69-76 (In Russ.). doi: 10.37489/0235-2990-2023-68-1-2-69-76Grainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: Risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191-204. doi: 10.1038/s41584-022-00755-xGrainger R, Kim AHJ, Conway R, Yazdany J, Robinson PC. COVID-19 in people with rheumatic diseases: Risks, outcomes, treatment considerations. Nat Rev Rheumatol. 2022;18(4):191-204. doi: 10.1038/s41584-022-00755-xНасонов ЕЛ, Белов БС, Лила АМ, Аронова ЕС, Гриднева ГИ, Кудрявцева АВ, и др. Течение и исходы COVID-19 у пациентов с иммуновоспалительными ревматическими заболеваниями: предварительные данные регистра НИИР/АРР-COVID-19 и обзор литературы. Научно-практическая ревматология. 2021;59(6):666-675. doi: 10.47360/1995-4484-2021-666-675Nasonov EL, Belov BS, Lila AM, Aronova ES, Gridneva GI, Kudryavtseva AV, et al. Course and outcomes of COVID-19 in patients with immunoinflammatory rheumatic diseases: Preliminary data from the NIIR/APP-COVID-19 registry and literature review. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice.2021;59(6):666-675 (In Russ.). doi: 10.47360/1995-4484-2021-666-675Мазуров ВИ, Беляева ИБ, Саранцева ЛЕ, Чудинов АЛ, Октябрьская ИВ, Башкинов РА, и др. Оценка влияния новой коронавирусной инфекции на клиническое течение ревматических заболеваний в реальной клинической практике. Медицинский алфавит. 2023;(9):7-16. doi: 10.33667/2078-5631-2023-9-7-16Mazurov VI, Belyaeva IB, Sarantseva LE, Chudinov AL, Oktyabrskaya IV, Bashkinov RA, et al. Evaluation of impact of new coronavirus infection on clinical course of rheumatic diseases in real clinical practice. Medical Alphabet. 2023;(9):7-16 (In Russ.). doi: 10.33667/2078-5631-2023-9-7-16Королев МА, Летягина ЕА, Сизиков АЭ, Богодерова ЛА, Убшаева ЮБ, Омельченко ВО, и др. Иммуновоспалительные ревматические заболевания и COVID-19: анализ клинических исходов по данным регистра пациентов Новосибирской области, получающих терапию генно-инженерными биологическими препаратами. Терапевтический архив. 2022;94(5):636-641. doi: 10.26442/00403660.2022.05.201502Korolev MA, Letyagina EA, Sizikov AE, Bogoderova LA, Ubshaeva YB, Omelchenko VO, et al. Immunoinflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs. Terapevticheskii arkhiv. 2022;94(5):636-641 (In Russ.). doi: 10.26442/00403660.2022.05.201502Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and metaanalysis. Rheumatol Int. 2021;41(5):851-861. doi: 10.1007/s00296-021-04803-9Wang Q, Liu J, Shao R, Han X, Su C, Lu W. Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: A systematic review and metaanalysis. Rheumatol Int. 2021;41(5):851-861. doi: 10.1007/s00296-021-04803-9Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi: 10.1002/art.42030Conway R, Grimshaw AA, Konig MF, Putman M, DuarteGarcía A, Tseng LY, et al.; COVID-19 Global Rheumatology Alliance. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol. 2022;74(5):766-775. doi: 10.1002/art.42030Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin Rheumatol. 2022;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1Wang F, Ma Y, Xu S, Liu H, Chen Y, Yang H, et al. Prevalence and risk of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis. Clin Rheumatol. 2022;41(7):2213-2223. doi: 10.1007/s10067-022-06087-1Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri M, Heidari B et al. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying antirheumatic drugs. Clin Rheumatol. 2021;40(10):4309-4315. doi: 10.1007/s10067-021-05779-4Yousefghahari B, Navari S, Sadeghi M, Soleimaniamiri S, Soleimaniamiri M, Heidari B et al. Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying antirheumatic drugs. Clin Rheumatol. 2021;40(10):4309-4315. doi: 10.1007/s10067-021-05779-4О рекомендациях по профилактике коронавирусной инфекции (COVID-19) среди работников: Письмо Роспотребнадзора № 02/6338-2020-15 от 07.04.2020. URL: https://www.consultant.ru/document/cons_doc_LAW_349881/ (Accessed: 2023)On the recommendations for the prevention of coronavirus infection (COVID-19) among employees: Letter of Rospotrebnadzor No. 02/6338-2020-15 d.d. 04.07.2020 (In Russ.). URL: https://www.consultant.ru/document/cons_doc_LAW_349881/ (Accessed: 2023)О дополнительных мерах по снижению рисков распространения COVID-19 в период сезонного подъема заболеваемости острыми респираторными вирусными инфекциями и гриппом: Постановление Главного государственного санитарного врача РФ № 31 от 16.10.2020 (ред. от 14.04.2022, с изм. от 20.06.2022). URL: https://www.consultant.ru/document/cons_doc_LAW_366116/On additional measures to reduce the risks of the spread of COVID-19 during the seasonal rise in the incidence of acute respiratory viral infections and influenza: Resolution of the Chief State Sanitary Doctor of the Russian Federation No. 31 d.d. 16.10.2020 (revised at 14.04.2022, as amended on 20.06.2022) (In Russ.). URL: https://www.consultant.ru/document/cons_doc_LAW_366116/Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immunemediated inflammatory diseases. Curr Opin Rheumatol. 2020;32(5):434-440. doi: 10.1097/BOR.0000000000000725Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immunemediated inflammatory diseases. Curr Opin Rheumatol. 2020;32(5):434-440. doi: 10.1097/BOR.0000000000000725Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al.; RIER Investigators Group; RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, et al.; RIER Investigators Group; RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study. Ann Rheum Dis. 2020;79(12):1544-1549. doi: 10.1136/annrheumdis-2020-218296Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021;7(1):e001464. doi: 10.1136/rmdopen-2020-001464Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.; COVID-19 Global Rheumatology Alliance. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384-391. doi: 10.1136/annrheumdis-2020-218946Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: A systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):384-391. doi: 10.1136/annrheumdis-2020-218946Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80(7):930-942. doi: 10.1136/annrheumdis-2020-219498Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, Godoy-Navarrete FJ, Cabezas-Lucena AM, Morales-Águila M, et al. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract. 2021;75(4):e13707. doi: 10.1111/ijcp.13707Mena Vázquez N, Manrique-Arija S, Cabezudo-García P, Godoy-Navarrete FJ, Cabezas-Lucena AM, Morales-Águila M, et al. Incidence and case fatality rate of COVID-19 in patients with inflammatory articular diseases. Int J Clin Pract. 2021;75(4):e13707. doi: 10.1111/ijcp.13707Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013-1016. doi: 10.1136/annrheumdis-2021-221539Papagoras C, Fragoulis GE, Zioga N, Simopoulou T, Deftereou K, Kalavri E, et al. Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases. Ann Rheum Dis. 2022;81(7):1013-1016. doi: 10.1136/annrheumdis-2021-221539Авдеев СН, Адамян ЛВ, Алексеева ЕИ, Багненко СФ, Баранов АА, Баранова НН, и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. М.;2020.Avdeev SN, Adamyan LV, Alekseeva EI, Bagnenko SF, Baranov AA, Baranova NN, et al. Prevention, diagnosis and treatment of new coronavirus infection (COVID-19). Interim guidelines. Moscow;2020 (In Russ.).Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 5 May 2023. URL: https://www.who.int/news/item/05-05-2023-statementon-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (Accessed: 30th June 2023).Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 5 May 2023. URL: https://www.who.int/news/item/05-05-2023-statementon-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (Accessed: 30th June 2023).Насонов ЕЛ, Лила АМ, Мазуров ВИ, Белов БС, Каратеев АЕ, Дубинина ТВ, и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021;59(3):239-254. doi: 10.47360/1995-4484-2021-239-254Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, et al. Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(3):239-254 (In Russ.). doi: 10.47360/1995-4484-2021-239-254

The authors declare that there are no conflicts of interest present.